Symbol Lookup

Wednesday June 29, 2016 12:16 PM ET. Data delayed 15 minutes.
4.86
0.07 (1.46%)
Bid/Lots
4.84/6
Ask/Lots
4.86/2
Open/Prev Close
4.93/4.79
Day Range
4.72-4.98
52-Week Range
4.26-23.61
Vol/Avg Daily Vol
152.5K/622.7K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Cara Therapeutics Starts Phase 2/3 Trial Of Anti-Itching Drug For Dialysis Patients
47 minutes ago by MT Newswires
Companies Mentioned: CARA
07:29 AM EDT, 06/29/2016 (MT Newswires) -- Cara Therapeutics (CARA) Wednesday said it has initiated patient recruitment for a phase 2/3 trial of its drug to treat dialysis patients suffering from moderate-to-severe uremic pruritus, or skin itching, ...
07:29 AM EDT, 06/29/2016 (MT Newswires) -- Cara Therapeutics (CARA) Wednesday said it has initiated patient recruitment for a phase 2/3 trial of its drug to treat dialysis patients suffering from moderate-to-severe uremic pruritus, or skin itchin...
Cara Therapeutics Initiates Adaptive Phase 2/3 Trial of I.V. CR845 for Treatment of Chronic Kidney Disease-Associated Pruritus
1 hour ago by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has initiated patient recruitment for an adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP), an intractable systemic itch condition in patients with chronic kidney disease (CKD), for which there are no approved therapies in the United States.

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

Jun 9, 2016

Cara Therapeutics to Present Preclinical Data at June Medical Meetings
8:00AM ET on Thursday Jun 09, 2016 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of preclinical data, including one late-breaking abstract, at the International Study Group Investigating Drugs as Reinforcers (to be held June 11, 2016) and the College on Problems of Drug Dependence 78 Annual Scientific Meeting (to be held June 11-16, 2016), both of which will take place in Palm Springs, California.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

Jun 6, 2016

BRIEF-Cara Therapeutics resumes patient recruitment
7:07AM ET on Monday Jun 06, 2016 by Thomson Reuters
Companies Mentioned: CARA

June 6 (Reuters) - Cara Therapeutics Inc :

* Resumed patient recruitment after FDA removed clinical hold on CLIN3001 adaptive phase 3 trial of I.V. CR8...

June 6 (Reuters) - Cara Therapeutics Inc :

* Resumed patient recruitment after FDA removed clinical hold on CLIN3001 adaptive phase 3 trial of I.V. CR8...

Cara Therapeutics Resumes Patient Recruitment for Adaptive Phase 3 Trial of I.V. CR845 in Postoperative Pain
7:00AM ET on Monday Jun 06, 2016 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has resumed patient recruitment after the U.S. Food and Drug Administration (FDA) removed a clinical hold on its CLIN3001 adaptive Phase 3 trial of I.V. CR845 for postoperative pain.

Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

← Newer12Older →

Peers Headlines

Today

Sector Update: Health Care
less than 1 minute ago by MT Newswires
Companies Mentioned: ANTH
12:12 PM EDT, 06/29/2016 (MT Newswires) -- Health care stocks were helping pace Wednesday's market gains, with the NYSE Health Care Index jumping 1.9% higher while shares of health care companies in the S&P 500 were up 1.8% as a group. In company...

Yesterday

MT Newswires After Hours News Movers
14 hours ago by MT Newswires
Companies Mentioned: NKE, ANTH, SHLM, ESPR, REED, AVAV, ECR, KMPH
05:39 PM EDT, 06/28/2016 (MT Newswires) -- Some of the stocks moving on news-driven events in Tuesday's after hours include: KMPH, +17% ESPR, -22% ANTH, -6.8% NKE, -6.6% SHLM, -1.3% ECR, -5.1% AVAV, -3.5% REED, -2% Price: 49.75, Change: -3.34, P...
BRIEF-Anthera provides clinical program updates for Blisibimod, Sollpura
14 hours ago by Thomson Reuters
Companies Mentioned: ANTH

June 28 (Reuters) - Anthera Pharmaceuticals Inc :

* Anthera provides clinical program updates for Blisibimod and Sollpura Source text for Eikon: Furthe...

Anthera Pharmaceuticals Slides After Hours as Data Shows BRIGHT-SC Study Endpoint Not Reached
15 hours ago by MT Newswires
Companies Mentioned: ANTH
05:10 PM EDT, 06/28/2016 (MT Newswires) -- Anthera Pharmaceuticals (ANTH) shares dropped 7% after the close on Tuesday as the company said interim data showed the numerical reduction in proteinuria in blisibimod versus placebo-treated patients at...
Anthera Provides Clinical Program Updates for Blisibimod and Sollpura(R)
15 hours ago by GlobeNewswire
Companies Mentioned: ANTH

-- Positive trends from BRIGHT-SC proof-of-concept study - study to continue

-- SOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016

-- First patients screened in Phase 3 CHABLIS 7.5 study of b...

Jun 22, 2016

Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
8:20AM ET on Wednesday Jun 22, 2016 by PR Newswire
Companies Mentioned: ANTH, PTLA, TRVN, NERV

On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad base...

Jun 21, 2016

BRIEF-ProQR to release topline data from proof of concept study of QR-010
9:30AM ET on Tuesday Jun 21, 2016 by Thomson Reuters
Companies Mentioned: PRQR

June 21 (Reuters) - ProQR Therapeutics NV:

* ProQR to release topline data from proof of concept study of QR-010 in cystic fibrosis patients at NACFC

*...

Jun 20, 2016

--Analyst Actions: Chardan Starts ProQR Therapeutics at Neutral With $4.50 PT
6:18AM ET on Monday Jun 20, 2016 by MT Newswires
Companies Mentioned: PRQR
06:18 AM EDT, 06/20/2016 (MT Newswires) -- Price: 4.93, Change: , Percent Change: ...

Jun 13, 2016

--Analyst Actions: Guggenheim Starts Merus at Buy
12:09PM ET on Monday Jun 13, 2016 by MT Newswires
Companies Mentioned: MRUS
12:09 PM EDT, 06/13/2016 (MT Newswires) -- Price: 9.13, Change: -0.02, Percent Change: -0.19 ...
--Analyst Actions: Citigroup Starts Merus NV at Buy, $14 PT
11:08AM ET on Monday Jun 13, 2016 by MT Newswires
Companies Mentioned: MRUS
11:08 AM EDT, 06/13/2016 (MT Newswires) -- Price: 9.21, Change: +0.06, Percent Change: +0.66 ...
← Newer12Older →